Advertisement


Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer

2015 NCCN Annual Conference

Advertisement

Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.



Related Videos

Issues in Oncology

Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates

Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.

Leukemia

Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.

Breast Cancer

Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer

Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation and a shorter course, the rising use of molecular profiling, and less invasive surgery and reduced amounts of surgery.

Gynecologic Cancers

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.

Breast Cancer

Melinda Telli, MD, on Evolving Treatment Strategies for Triple-Negative Breast Cancer

Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.

Advertisement

Advertisement




Advertisement